TP53 Mutation Predicts Worse Survival and Earlier Local Progression in Patients with Hepatocellular Carcinoma Treated with Transarterial Embolization
The aim of this study was to evaluate associations between TP53 status and outcomes after transarterial embolization (TAE) for the treatment of patients with hepatocellular carcinoma (HCC). This single-institution study included patients from 1/2014 to 6/2022 who underwent TAE of HCC and genomic ana...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/1/51 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588674447966208 |
|---|---|
| author | Ken Zhao Anita Karimi Luke Kelly Elena Petre Brett Marinelli Erica S. Alexander Vlasios S. Sotirchos Joseph P. Erinjeri Anne Covey Constantinos T. Sofocleous James J. Harding William Jarnagin Carlie Sigel Efsevia Vakiani Etay Ziv Hooman Yarmohammadi |
| author_facet | Ken Zhao Anita Karimi Luke Kelly Elena Petre Brett Marinelli Erica S. Alexander Vlasios S. Sotirchos Joseph P. Erinjeri Anne Covey Constantinos T. Sofocleous James J. Harding William Jarnagin Carlie Sigel Efsevia Vakiani Etay Ziv Hooman Yarmohammadi |
| author_sort | Ken Zhao |
| collection | DOAJ |
| description | The aim of this study was to evaluate associations between TP53 status and outcomes after transarterial embolization (TAE) for the treatment of patients with hepatocellular carcinoma (HCC). This single-institution study included patients from 1/2014 to 6/2022 who underwent TAE of HCC and genomic analysis of tumoral tissue. The primary outcome was overall survival (OS) with relation to TP53 status, and the secondary outcome was the time to progression. Survival analysis was performed using the Kaplan–Meier method. The time to progression with death or the last patient contact without progression as competing risks were used to obtain a cumulative incidence function, and the association with TP53 status was evaluated using the Gray test. In total, 75 patients (63 men) with a median age of 70.0 (IQR 62.0–76.3) years were included. Of these, 26/75 (34.7%) patients had TP53-mutant HCC. Patients with TP53-mutant HCC had a significantly worse median OS of 15.2 (95% CI, 9.5–29.3) months, versus 31.2 (95% CI, 21.2–52.4) months as the median OS (<i>p</i> = 0.023) for TP53 wild-type HCC. Competing risk analysis showed a shorter time to local hepatic progression (at the site of the previously treated tumor) after TAE in patients with TP53-mutant HCC. The cumulative incidences of local progression at 6 and 12 months for TP53-mutant HCC were 65.4% and 84.6%, versus 40.8% and 55.1% for TP53 wild-type HCC (<i>p</i> = 0.0072). A TP53 mutation may predict a worse overall survival and a shorter time to local progression in HCC patients treated with TAE. |
| format | Article |
| id | doaj-art-1acbba12ad7647959da819ff077c60d8 |
| institution | Kabale University |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-1acbba12ad7647959da819ff077c60d82025-01-24T13:28:30ZengMDPI AGCurrent Oncology1198-00521718-77292025-01-013215110.3390/curroncol32010051TP53 Mutation Predicts Worse Survival and Earlier Local Progression in Patients with Hepatocellular Carcinoma Treated with Transarterial EmbolizationKen Zhao0Anita Karimi1Luke Kelly2Elena Petre3Brett Marinelli4Erica S. Alexander5Vlasios S. Sotirchos6Joseph P. Erinjeri7Anne Covey8Constantinos T. Sofocleous9James J. Harding10William Jarnagin11Carlie Sigel12Efsevia Vakiani13Etay Ziv14Hooman Yarmohammadi15Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USADepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USADepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USADepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USADepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USADepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USADepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USADepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USADepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USADepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USADepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USADepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USADepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USADepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USADepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USADepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USAThe aim of this study was to evaluate associations between TP53 status and outcomes after transarterial embolization (TAE) for the treatment of patients with hepatocellular carcinoma (HCC). This single-institution study included patients from 1/2014 to 6/2022 who underwent TAE of HCC and genomic analysis of tumoral tissue. The primary outcome was overall survival (OS) with relation to TP53 status, and the secondary outcome was the time to progression. Survival analysis was performed using the Kaplan–Meier method. The time to progression with death or the last patient contact without progression as competing risks were used to obtain a cumulative incidence function, and the association with TP53 status was evaluated using the Gray test. In total, 75 patients (63 men) with a median age of 70.0 (IQR 62.0–76.3) years were included. Of these, 26/75 (34.7%) patients had TP53-mutant HCC. Patients with TP53-mutant HCC had a significantly worse median OS of 15.2 (95% CI, 9.5–29.3) months, versus 31.2 (95% CI, 21.2–52.4) months as the median OS (<i>p</i> = 0.023) for TP53 wild-type HCC. Competing risk analysis showed a shorter time to local hepatic progression (at the site of the previously treated tumor) after TAE in patients with TP53-mutant HCC. The cumulative incidences of local progression at 6 and 12 months for TP53-mutant HCC were 65.4% and 84.6%, versus 40.8% and 55.1% for TP53 wild-type HCC (<i>p</i> = 0.0072). A TP53 mutation may predict a worse overall survival and a shorter time to local progression in HCC patients treated with TAE.https://www.mdpi.com/1718-7729/32/1/51hepatocellular carcinomainterventional oncologytransarterial embolizationtumor protein p53 |
| spellingShingle | Ken Zhao Anita Karimi Luke Kelly Elena Petre Brett Marinelli Erica S. Alexander Vlasios S. Sotirchos Joseph P. Erinjeri Anne Covey Constantinos T. Sofocleous James J. Harding William Jarnagin Carlie Sigel Efsevia Vakiani Etay Ziv Hooman Yarmohammadi TP53 Mutation Predicts Worse Survival and Earlier Local Progression in Patients with Hepatocellular Carcinoma Treated with Transarterial Embolization Current Oncology hepatocellular carcinoma interventional oncology transarterial embolization tumor protein p53 |
| title | TP53 Mutation Predicts Worse Survival and Earlier Local Progression in Patients with Hepatocellular Carcinoma Treated with Transarterial Embolization |
| title_full | TP53 Mutation Predicts Worse Survival and Earlier Local Progression in Patients with Hepatocellular Carcinoma Treated with Transarterial Embolization |
| title_fullStr | TP53 Mutation Predicts Worse Survival and Earlier Local Progression in Patients with Hepatocellular Carcinoma Treated with Transarterial Embolization |
| title_full_unstemmed | TP53 Mutation Predicts Worse Survival and Earlier Local Progression in Patients with Hepatocellular Carcinoma Treated with Transarterial Embolization |
| title_short | TP53 Mutation Predicts Worse Survival and Earlier Local Progression in Patients with Hepatocellular Carcinoma Treated with Transarterial Embolization |
| title_sort | tp53 mutation predicts worse survival and earlier local progression in patients with hepatocellular carcinoma treated with transarterial embolization |
| topic | hepatocellular carcinoma interventional oncology transarterial embolization tumor protein p53 |
| url | https://www.mdpi.com/1718-7729/32/1/51 |
| work_keys_str_mv | AT kenzhao tp53mutationpredictsworsesurvivalandearlierlocalprogressioninpatientswithhepatocellularcarcinomatreatedwithtransarterialembolization AT anitakarimi tp53mutationpredictsworsesurvivalandearlierlocalprogressioninpatientswithhepatocellularcarcinomatreatedwithtransarterialembolization AT lukekelly tp53mutationpredictsworsesurvivalandearlierlocalprogressioninpatientswithhepatocellularcarcinomatreatedwithtransarterialembolization AT elenapetre tp53mutationpredictsworsesurvivalandearlierlocalprogressioninpatientswithhepatocellularcarcinomatreatedwithtransarterialembolization AT brettmarinelli tp53mutationpredictsworsesurvivalandearlierlocalprogressioninpatientswithhepatocellularcarcinomatreatedwithtransarterialembolization AT ericasalexander tp53mutationpredictsworsesurvivalandearlierlocalprogressioninpatientswithhepatocellularcarcinomatreatedwithtransarterialembolization AT vlasiosssotirchos tp53mutationpredictsworsesurvivalandearlierlocalprogressioninpatientswithhepatocellularcarcinomatreatedwithtransarterialembolization AT josephperinjeri tp53mutationpredictsworsesurvivalandearlierlocalprogressioninpatientswithhepatocellularcarcinomatreatedwithtransarterialembolization AT annecovey tp53mutationpredictsworsesurvivalandearlierlocalprogressioninpatientswithhepatocellularcarcinomatreatedwithtransarterialembolization AT constantinostsofocleous tp53mutationpredictsworsesurvivalandearlierlocalprogressioninpatientswithhepatocellularcarcinomatreatedwithtransarterialembolization AT jamesjharding tp53mutationpredictsworsesurvivalandearlierlocalprogressioninpatientswithhepatocellularcarcinomatreatedwithtransarterialembolization AT williamjarnagin tp53mutationpredictsworsesurvivalandearlierlocalprogressioninpatientswithhepatocellularcarcinomatreatedwithtransarterialembolization AT carliesigel tp53mutationpredictsworsesurvivalandearlierlocalprogressioninpatientswithhepatocellularcarcinomatreatedwithtransarterialembolization AT efseviavakiani tp53mutationpredictsworsesurvivalandearlierlocalprogressioninpatientswithhepatocellularcarcinomatreatedwithtransarterialembolization AT etayziv tp53mutationpredictsworsesurvivalandearlierlocalprogressioninpatientswithhepatocellularcarcinomatreatedwithtransarterialembolization AT hoomanyarmohammadi tp53mutationpredictsworsesurvivalandearlierlocalprogressioninpatientswithhepatocellularcarcinomatreatedwithtransarterialembolization |